Next Article in Journal
Temporal Trends in Patients with Peripheral Artery Disease Influenced by COVID-19 Pandemic
Next Article in Special Issue
Comaneci-Assisted Coiling of Wide-Necked Intracranial Aneurysm: A Single-Center Preliminary Experience
Previous Article in Journal
Temporal Change in Anterior Chamber Depth after Combined Vitrectomy and Cataract Surgery Using Different Sizes of Intraocular Lens
Previous Article in Special Issue
Interventional Radiological Management and Prevention of Complications after Pancreatic Surgery: Drainage, Embolization and Islet Auto-Transplantation
 
 
Article
Peer-Review Record

Role of Bronchial Artery Embolization as Early Treatment Option in Stable Cystic Fibrosis Patients with Sub-Massive Hemoptysis: Personal Experience and Literature Review

J. Clin. Med. 2022, 11(21), 6432; https://doi.org/10.3390/jcm11216432
by Chiara Floridi 1,2,3,*, Pietro Boscarato 3, Claudio Ventura 1, Alessandra Bruno 1, Nicolo’ Rossini 1, Michela Baldassari 1, Cecilia Lanza 2, Benedetta Fabrizzi 4, Roberto Candelari 3 and Andrea Giovagnoni 1,2
Reviewer 2:
J. Clin. Med. 2022, 11(21), 6432; https://doi.org/10.3390/jcm11216432
Submission received: 3 September 2022 / Revised: 19 October 2022 / Accepted: 27 October 2022 / Published: 30 October 2022
(This article belongs to the Special Issue Embolization Techniques: State of the Art and Future Perspectives)

Round 1

Reviewer 1 Report

This article investigates the role of bronchial artery embolization as early treatment option in stable cystic fibrosis patients with submassive hemoptysis. Although the topic is interesting, the context of the research is not sufficiently described and the discussion in several parts is a mere repetition of the results.

Specific comments:

- Introduction

The introduction is divided into too many paragraphs, paragraphs should be combined.

The MAV's full name must be written and MAV followed by parentheses.

 

- Materials and Methods

 

The FOV's full name must be written and FOV followed by parentheses.

 

- Results

In Table 3, "N° pz", "N° proc.", "PVA" and "TAG" explanations should be written below the table.

In Figure 4, differences between groups should be marked with *. Statistical significance level and method should be added to the subtitle of Figure 4.

 

- Discussion

Discussion section in the present form is a repetition of the results. If possible, this section should critically analyse and interpret the findings of the study.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Dear Authors,

-It would be appropriate to indicate the number of patients included in the study and their gender distribution in the patient selection section. How many patients the study was conducted on is understood later in the manuscript. Ethics committee approval was obtained for this study.

-The acceptance number of the ethics committee should be indicated in parentheses.

-The English of the manuscript should be reviewed and typos corrected (eg line-154 salective-selective).

-N, indicating the number of cases, should be written in lower case (such as n=13-line 227, n=19-line 241).

-In the initial embolization period, respiratory infection would be more appropriate instead of ‘chronic respiratory infection’ terminology for infection or coinfection. Or did the patients really have a chronic lung infection?

-Do the abbreviations Y and N mean yes and no under the heading where the significance importance of right and left vessel calibers are indicated in the table? (Table 2). The explanations of the abbreviations in the table should be stated under or inside the table.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop